Doing the Math on Meningitis Vaccinations

With billions of dollars in annual revenue at stake, vaccine makers are pushing meningitis vaccine mandates across the country. Vaccine issues are always complex, but advocates of the meningitis mandate should consider some simple math.

This past Thursday, the University of Colorado-Boulder student government passed a resolution asking the CDC’s Advisory Committee on Immunization Practices (ACIP) to recommend meningococcal vaccines for all incoming college students. ACIP will consider CU-Boulder’s resolution on June 24. ACIP’s first agenda topic will be the debate over recommending the meningococcal B vaccines for adolescents and college students.

With billions of dollars in annual revenue at stake, vaccine makers are pushing meningitis vaccine mandates across the country. Vaccine issues are always complex, but advocates of the meningitis mandate should consider some simple math.

Meningococcal meningitis is exceedingly rare. There were only  about 390 cases in the U.S. last year. In a population of 319 million, that adds up to one case in 817,949 people. There were only three meningococcal meningitis cases in Colorado last year — one resulting in death. The CDC has approved three vaccines targeting the A, C, Y and W135 strains of meningitis: Menactra, Menveo and Menomune, which still contains significant mercury concentrations in multi-dose vials. These vaccines are effective in providing immunity to those strains of meningitis in only 85 percent of people who receive them.

Thirty percent of the meningitis cases are the B strain, which typically occur in college-aged kids and against which the three vaccines are completely ineffective.

The FDA recently approved two B strain meningococcal vaccines, Trumenba and Bexsero. Vaccine makers are pushing government officials to add them to the recommended schedule for the fall semester. Critics have faulted the government’s expedited safety and efficiency testing for the new B strain vaccines citing glaring lapses in safety protocols including the absence of inactive placebos. In addition, both new B vaccines are “pregnancy category B,” meaning that they should be administered to pregnant women only when necessary. Neither vaccine has been tested for carcinogenicity, mutagenicity or effects on male fertility.

According to their package inserts, Menactra and Menveo produce “serious adverse events” in 1 percent of recipients. Menomune, with its hefty mercury load, sickens 1.3 percent of those receiving it. According to the CDC Pink Book, 0.3 percent of those with “serious adverse events” from meningitis vaccines will die. So here is the math calculation that thoughtful student governments in Colorado must consider: If you inoculate Colorado’s 400,000 college students with the older vaccines, you can expect 4,000 serious adverse events and 12 dead. We do not yet know the effects of widespread vaccination of the hastily-expedited B vaccines, but according to their package inserts, about 2 percent of students who receive the B vaccine will be sickened or hospitalized with a serious adverse event. This could translate into an additional 8,000 sick students and 24 deaths, for a total of 12,000 sick and 36 dead in the attempt to possibly avert three meningitis cases….

https://www.greenmedinfo.health/blog/doing-math-meningitis-vaccinations

error

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.